GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Vera Therapeutics Inc.
Vera Therapeutics is a biotech company focused on treating immune-related kidney diseases. Its stock price is highly volatile and dependent on clinical trial results. The chart reflects investor hopes for a new standard of treatment in this complex area.
Share prices of companies in the market segment - Pharma immune
Vera Therapeutics is a biotech company focused on treating immune-related kidney diseases. We classify it as a Pharma-Immune company, and the chart below shows the dynamics of this entire segment, where the company's value is entirely dependent on the success of clinical trials.
Broad Market Index - GURU.Markets
Vera Therapeutics is a biopharmaceutical company developing drugs to treat immunological diseases, particularly kidney disease. It is a component of the GURU.Markets index. The chart below shows the market. See how Vera shares compare to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
VERA - Daily change in the company's share price Vera Therapeutics Inc.
Shares of Vera Therapeutics, a biopharmaceutical company, exhibit high volatility, as measured by change_co. This metric reflects sensitivity to clinical trial results. This metric is a key component of formulas on System.GURU.Markets for risk analysis in the biotech sector.
Daily change in the price of a set of shares in a market segment - Pharma immune
Vera Therapeutics, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with VERA, which focuses on immune disease treatments, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Vera Therapeutics is a biopharmaceutical company specializing in drugs for the treatment of immune diseases. Immunology is a cutting-edge but highly volatile segment of biotechnology. The chart below shows average daily fluctuations in this area, allowing you to assess Vera's stock performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Vera Therapeutics Inc.
Vera is a biotech company focused on immunology. Its shares, like many in the sector, are highly volatile and react to news about clinical trials. These science-driven movements are part of the complex and diverse landscape of the entire stock market.
Annual dynamics of market capitalization of the market segment - Pharma immune
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing drugs for the treatment of rare immunological diseases. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs in this field.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Vera Therapeutics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Vera Therapeutics Inc.
Vera, a clinical-stage biotech company specializing in the treatment of immunological diseases, has sharp monthly fluctuations reflecting the release of clinical trial data, which is key to its valuation.
Monthly dynamics of market capitalization of the market segment - Pharma immune
Vera Therapeutics is a clinical-stage biotech company focused on developing treatments for immunological diseases, particularly those affecting the kidneys. Its valuation depends on the success of clinical trials. The chart below shows the overall dynamics of the biotech sector, known for its risks and potential.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Vera Therapeutics, Inc. is a late-stage biopharmaceutical company focused on developing treatments for severe immunological diseases. The company's future depends on the success of its clinical trials. The broader market chart serves as a backdrop to illustrate how news about its drugs and potential for treating rare kidney diseases has driven its stock price movement independently.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Vera Therapeutics Inc.
Shares of Vera Therapeutics, a biopharmaceutical company focused on treating immunological diseases, reflect hope in this complex area of medicine every week. Their price movements reflect clinical trial data demonstrating the potential of their drugs.
Weekly dynamics of market capitalization of the market segment - Pharma immune
Immunology-focused biotech is a sector where weekly performance depends on clinical data. The search for new treatments for autoimmune diseases is a common trend across the board. The chart illustrates this backdrop, which allows us to assess Vera Therapeutics' potential.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Vera Therapeutics is a biotech company specializing in the treatment of immune diseases. Shares of such innovative companies often move independently of the market. This chart will help you understand: is Vera living in its own world of clinical trials, or are overall market conditions and risk appetite influencing its stock price?
Market capitalization of the company, segment and market as a whole
VERA - Market capitalization of the company Vera Therapeutics Inc.
Vera Therapeutics' market capitalization tells the story of a biotech company focused on treating immunological kidney diseases. Its volatile price action is a direct response to clinical trial data for its lead drug. Its dynamics reflect investors' assessments of its scientific potential and the chances of success in treating complex and widespread diseases.
VERA - Share of the company's market capitalization Vera Therapeutics Inc. within the market segment - Pharma immune
Vera Therapeutics is a biotech company focused on developing drugs to treat severe immunological diseases. Its market share currently reflects the potential of its lead candidate. Its market cap is a bet on the success of clinical trials and the hope of a new standard of treatment for patients.
Market capitalization of the market segment - Pharma immune
Vera Therapeutics is a clinical-stage biotech company focused on treating immunological diseases. The chart below shows the overall market capitalization of this sector. Its volatility reflects the hopes and risks associated with new drug development, where any result can change everything.
Market capitalization of all companies included in a broad market index - GURU.Markets
Vera Therapeutics is a biotech company developing drugs to treat immunological kidney diseases. Its market capitalization is based on the potential of its lead candidate. The chart below shows the economic weight of companies targeting specific immune diseases.
Book value capitalization of the company, segment and market as a whole
VERA - Book value capitalization of the company Vera Therapeutics Inc.
Vera Therapeutics' balance sheet represents its capital earmarked for late-stage clinical trials of a drug for the treatment of a rare autoimmune kidney disease. This is a real, scientific foundation aimed at solving a serious medical problem. How has this biotech asset changed? The chart below shows its dynamics.
VERA - Share of the company's book capitalization Vera Therapeutics Inc. within the market segment - Pharma immune
Vera Therapeutics, a biopharmaceutical company, relies on laboratory facilities to conduct its clinical research and development. The chart shows the share of these science-intensive tangible assets in the sector, reflecting the physical foundation of its work on treating immune diseases.
Market segment balance sheet capitalization - Pharma immune
Developing drugs to treat autoimmune diseases, as the BCap_Seg chart for biotech shows, is a science-intensive endeavor. Vera Therapeutics operates in this environment. Its capital is invested in clinical research and intellectual property, not in building giant factories.
Book value of all companies included in the broad market index - GURU.Markets
Vera Therapeutics' assets are not product lines, but a valuable portfolio of intellectual property and clinical trial data in immunology. The book value reflects the capital invested in the scientific foundation that forms the foundation for future therapeutics.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Vera Therapeutics Inc.
Vera Therapeutics is a biotech company developing drugs to treat immune diseases. Its balance sheet is funded by research. Its market capitalization is a bet on the success of its lead drug candidate. The MvsBCap chart will exhibit extreme volatility, reacting to every news item about the progress of clinical trials.
Market to book capitalization ratio in a market segment - Pharma immune
Vera Therapeutics is a biotech company focused on treating immunological diseases. Its value depends almost entirely on the success of clinical trials. The chart shows how investors value the scientific potential of its developments, which is many times greater than its tangible assets.
Market to book capitalization ratio for the market as a whole
Vera Therapeutics is a biotech company focused on treating immunological diseases. Its market value depends almost entirely on the success of clinical trials of its lead drug. This chart is a classic example of biotech, where investors evaluate not current assets but the likelihood of a future scientific breakthrough.
Debts of the company, segment and market as a whole
VERA - Company debts Vera Therapeutics Inc.
Vera Therapeutics, a clinical-stage biotech, raises capital exclusively to fund its immunology research. Until drug approval, the company relies entirely on external funding to support its operations. This chart illustrates how the company manages its financial resources during the long and risky journey of drug discovery.
Market segment debts - Pharma immune
Vera Therapeutics is a clinical-stage biotech company focused on treating immunological diseases. Funding lengthy and expensive clinical trials is a key challenge for such companies. This chart illustrates how Vera is building its financial strategy to bring its drug candidates to regulatory approval.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Vera Therapeutics Inc.
Vera Therapeutics is a biotech company focused on treating immunological diseases. The chart shows how it finances its clinical development. For a company in the research stage with no commercial products, raising debt is a significant risk. Its presence and size indicate a high stake in the future success of its therapy.
Market segment debt to market segment book capitalization - Pharma immune
Vera Therapeutics is a clinical-stage biotech company focused on immunology. This chart for the biotech sector illustrates how the industry as a whole raises capital to fund lengthy and expensive research. It provides context for assessing the financial viability of a company that does not yet have commercial products.
Debt to book value of all companies in the market
Vera Therapeutics is a biotech company. Its funding depends on investors' confidence in its future drugs. This chart reflects the overall risk appetite in the economy. For a company without revenue, it helps understand how its debt or equity financing model compares to the overall market.
P/E of the company, segment and market as a whole
P/E - Vera Therapeutics Inc.
This chart for Vera Therapeutics, a biopharmaceutical company focused on treating immunological diseases, reflects investor expectations. High numbers, or lack thereof, indicate not current profits, but the potential of its drugs in clinical trials to become breakthroughs in the treatment of serious diseases.
P/E of the market segment - Pharma immune
This chart shows the average P/E valuation for the biopharmaceutical industry in which Vera Therapeutics operates. The sector's very high average valuation reflects hopes for scientific breakthroughs. The chart illustrates this general backdrop against which the risks and potential success of Vera's specific immunology developments are assessed.
P/E of the market as a whole
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Its future depends on the success of its clinical trials. This chart, reflecting overall investor risk appetite, shows how willing the market is to fund Vera's research in the hopes of creating a new standard of care.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Vera Therapeutics Inc.
Vera Therapeutics is a biotechnology company developing drugs for the treatment of immunological kidney diseases. The chart reflects investors' speculative expectations for future revenue, which are entirely dependent on the success of clinical trials and the potential of its lead drug candidate to become a new standard of care.
%20P%2FE%20Vera%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Vera-Therapeutics-Inc.&v=1772702530548 "Chart of the company's future (projected) P/E Vera Therapeutics Inc.")
Future (projected) P/E of the market segment - Pharma immune
Vera Therapeutics is a clinical-stage biotech company focused on treating serious immunological diseases. Its future depends on the success of its clinical trials. The chart shows the average profitability expectations for the sector, helping to understand how high investor expectations are for its lead drug candidate.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772702530560 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
Vera Therapeutics is a clinical-stage biotech company developing drugs to treat serious immunological diseases. Its value depends almost entirely on the results of future clinical trials. This graph of overall risk appetite shows how willing investors are to invest in long-term and uncertain biotech projects.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772702530571 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Vera Therapeutics Inc.
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Its financial metrics reflect clinical research expenses. This chart illustrates its investments in research, which are aimed at developing new therapeutic options for patients and future profits.
Profit of companies in the market segment - Pharma immune
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Its future depends on the success of its trials. This chart reflects the broader picture in the immunopharmaceutical sector, where the potential for breakthrough drugs attracts investors despite the high risks.
Overall market profit
Vera Therapeutics, Inc. is a biotechnology company focused on treating immunological diseases. Its future depends on the success of clinical trials and drug approvals. This process is completely isolated from the macroeconomic trends shown in this chart. The company's value is determined by scientific progress, not the current state of the economy.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Vera Therapeutics Inc.
Vera Therapeutics is a clinical-stage biotechnology company focused on the treatment of immunological diseases. Future profits are entirely dependent on the success of clinical trials and subsequent approval of its drugs. This chart represents analysts' speculative expectations regarding the scientific and commercial potential of Vera's developments.
%20profit%20of%20the%20company%20Vera%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Vera-Therapeutics-Inc.&v=1772702530615 "Graph of future (projected) profit of the company Vera Therapeutics Inc.")
Future (predicted) profit of companies in the market segment - Pharma immune
Vera Therapeutics is a biotechnology company focused on developing drugs to treat serious immunological diseases, particularly IgA nephropathy. Its future depends on the success of clinical trials and regulatory approval. This chart shows revenue projections for the immunopharmaceuticals sector, providing context for assessing Vera's scientific potential.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772702530632 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
Vera Therapeutics, Inc. is a biotechnology company focused on treating immunological diseases. Its valuation depends on the success of clinical development. The overall economic environment, reflected in this chart, influences the availability of capital and investor willingness to fund early-stage companies like Vera.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772702530640 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Vera Therapeutics Inc.
Vera Therapeutics is a clinical-stage biotech company focused on treating immunological diseases. There is no revenue at this stage. This chart reflects purely speculative investor expectations. Its performance is based on clinical trial news, not financial performance.
P/S market segment - Pharma immune
Vera Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for serious immunological diseases. Their lead candidate aims to modify the course of the disease, not simply suppress symptoms. This chart reflects the average revenue estimate for the sector, providing insight into market expectations for Vera's innovative approach.
P/S of the market as a whole
Vera Therapeutics is a clinical-stage biotech focused on developing treatments for serious immunological diseases. The company's valuation is based on the potential of its lead drug. This chart highlights the difference between valuations based on future expectations and the average market valuation based on current revenue.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Vera Therapeutics Inc.
Vera Therapeutics is a biotechnology company focused on developing drugs for the treatment of immunological diseases. For a clinical-stage company, future revenue estimates are hypothetical but important. They reflect investors' confidence in Vera's scientific platform and the commercial potential of its drug candidates to address unmet medical needs.
%20P%2FS%20Vera%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Vera-Therapeutics-Inc.&v=1772702530692 "The graph of the company's future (projected) P/S Vera Therapeutics Inc.")
Future (projected) P/S of the market segment - Pharma immune
Vera Therapeutics is a biotech company specializing in the development of treatments for immunological diseases. Its lead candidate targets IgA nephropathy, a rare kidney disease. This chart compares the company's estimated future sales with industry expectations, showing how investors view the scientific potential and commercial prospects of its developments.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772702530725 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
Vera Therapeutics is a biotech company focused on treating immunological diseases. Its value is based on the potential of its future drugs. In the overall revenue growth picture illustrated by the chart, Vera represents a sector where market capitalization reflects future rather than current revenue.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772702530754 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Vera Therapeutics Inc.
This chart shows the revenue of Vera Therapeutics, a clinical-stage biotech developing drugs for immunological diseases. Its current revenue may be zero or negligible, consisting of grants. Future growth will depend on successful trials and commercialization of its developments.
Sales of companies in the market segment - Pharma immune
Vera Therapeutics is a clinical-stage biotech company focused on treating immunological diseases. It currently has no sales revenue. Its future revenue structure will depend on the success of its lead candidate, atasicept, which is typical for companies in its sector, where the risks and potential rewards are very high.
Overall market sales
Vera Therapeutics is a clinical-stage biotech company focused on treating immunological diseases. Its value and prospects are determined solely by the results of its research and the potential of its drugs. This overall economic performance chart is not directly related to the company's mission to create medical breakthroughs.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Vera Therapeutics Inc.
Vera Therapeutics is a clinical-stage biotechnology company focused on the treatment of immunological diseases. The company does not yet have commercial products, and its future revenue depends on the success of clinical trials. This chart reflects analysts' expectations for potential sales of its drugs if they are approved by regulators.
%20sales%20of%20the%20company%20Vera%20Therapeutics%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Vera-Therapeutics-Inc.&v=1772702530795 "Schedule of future (projected) sales of the company Vera Therapeutics Inc.")
Future (projected) sales of companies in the market segment - Pharma immune
Vera Therapeutics is a biotech company focused on treating immunological diseases. This chart shows the outlook for the immunology sector. Is the market expected to grow due to the development of new, more effective treatments for autoimmune disorders? This helps assess the overall scientific and commercial potential of the industry.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772702530801 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
Vera Therapeutics is a biotechnology company specializing in the development of treatments for immunological diseases. Its success and value depend on the results of clinical trials and regulatory approvals. The general economic trends shown in this chart do not directly impact the company's scientific and clinical activities.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772702530826 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Vera Therapeutics Inc.
Vera Therapeutics is a biotechnology company focused on developing treatments for immunological diseases. This chart reflects its financial performance at the clinical trial stage. Profitability is a long-term goal, and current metrics demonstrate the level of investment in research and development, which could lead to the development of new effective drugs.
Market segment marginality - Pharma immune
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing drugs for the treatment of immunological diseases. The company has no commercial products and relies entirely on R&D investments. This chart reflects its current financial performance, with profitability a long-term goal dependent on the success of clinical trials.
Market marginality as a whole
Vera Therapeutics, a clinical-stage biopharmaceutical company, is focused on treating immunological diseases. Its future depends on successful trials and capital raising. This total return chart reflects the investor appetite for risk required to finance long-term, capital-intensive biotech development.
Employees in the company, segment and market as a whole
Number of employees in the company Vera Therapeutics Inc.
Vera Therapeutics is a clinical-stage biotech company focused on treating immunological diseases. Its small staff consists of scientists and clinical research specialists. This graph shows how the team is growing as its lead drug candidate progresses through key phases of testing, approaching potential approval.
Share of the company's employees Vera Therapeutics Inc. within the market segment - Pharma immune
Vera Therapeutics is a clinical-stage biotech company focused on developing treatments for immunological diseases. Its team consists primarily of scientists and clinical trial specialists. This graph shows the company's share of the biotech labor market, and its dynamics reflect the progress of its research and development toward commercialization.
Number of employees in the market segment - Pharma immune
Vera Therapeutics is a biopharmaceutical company focused on treating immunological kidney diseases. This chart shows employment in the immunopharmaceutical sector. The growth in the number of specialists in this field is driven by scientific breakthroughs. Vera's targeted approach to treating specific rare kidney diseases may lead to the development of breakthrough therapies.
Number of employees in the market as a whole
Vera Therapeutics is a biotech company focused on treating immunological diseases. Its staff consists of scientists and clinicians. The team's growth, compared to the overall workforce in this chart, speaks not to economics but to progress in clinical trials and the potential of its drugs to address unmet medical needs.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Vera Therapeutics Inc. (VERA)
Vera Therapeutics is a biotech company. This chart shows how the market values their scientific potential in immunology. Their entire value could be captured in a single promising development. Their per-employee market cap could be extremely high, reflecting not current sales but investor expectations for a future blockbuster.
%20of%20the%20company%20Vera%20Therapeutics%20Inc.%20(VERA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Vera-Therapeutics-Inc.-VERA&v=1772702530944 "Chart of market capitalization per employee (in thousands of dollars) of the company Vera Therapeutics Inc. (VERA)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
Vera Therapeutics (VERA) is a clinical-stage biotech developing drugs for the treatment of immunological diseases, specifically IgA nephropathy (a kidney disease). This chart shows the average market capitalization per employee in the sector. It helps assess how the market values their R&D portfolio and scientific team per scientist.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772702530951 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
Vera Therapeutics is a clinical-stage biotech company developing drugs for the treatment of immunological diseases. Its valuation is based on future potential. The chart shows a high valuation per employee, as investors are pricing in the company's expectations of successful clinical trials and commercialization of its lead candidate.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772702530959 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Vera Therapeutics Inc. (VERA)
Vera Therapeutics is a clinical-stage biotech company focused on immunological diseases. This chart will likely reflect the net loss per employee. This is standard for R&D companies: every scientist and doctor is an investment in a future drug. This metric reflects the "burn rate" of capital spent on personnel.
%20Chart%20Vera%20Therapeutics%20Inc.%20(VERA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Vera-Therapeutics-Inc.-VERA&v=1772702530982 "Company Profit Per Employee (in thousands of dollars) Chart Vera Therapeutics Inc. (VERA)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
Vera Therapeutics (VERA) is an R&D biotech company (immunology, nephrology). This chart shows the benchmark for "Immune Pharma" (R&D). The average profit per employee in this sector (venture R&D) is *negative*. This benchmark reflects the "burning" of money in the hopes of one or two mega-successes. The entire sector is an R&D race, spending billions on elite scientists.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772702530990 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
Vera Therapeutics is a clinical-stage biotech company specializing in immunology (kidney disease). It's an R&D company. Like Celldex, this chart shows the operating loss per employee—the "cost" of conducting expensive clinical trials per research staff while the company moves toward commercialization.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772702530996 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Vera Therapeutics Inc. (VERA)
Vera Therapeutics is a clinical-stage biotech company focused on immunology. At this stage, revenue per employee may be nonexistent. This graph represents an estimate of future potential: if their drugs are successful, this figure could skyrocket, reflecting the enormous value of the intellectual property generated.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Vera-Therapeutics-Inc.-VERA&v=1772702531021 "Sales chart per company employee Vera Therapeutics Inc. (VERA)")
Sales per employee in the market segment - Pharma immune
Vera Therapeutics is a clinical-stage biotech company focused on treating immunological diseases (such as kidney disease). This is pure R&D. This chart shows the average output for the sector. For VERA, which does not yet have commercial revenue, it is more of a leading indicator of personnel costs relative to the biotech sector average.
Sales per employee for the market as a whole
Vera Therapeutics is a clinical-stage biotech company focused on immunological diseases. At this stage, the company likely has no significant revenue. This chart illustrates its capital burn: the company is investing in its research team in hopes of a future breakthrough.
Short shares by company, segment and market as a whole
Shares shorted by company Vera Therapeutics Inc. (VERA)
Vera Therapeutics (VERA) is a clinical-stage biotech focused on treating autoimmune kidney diseases. This chart shows the number of short positions. The high short position reflects binary risk: bears are betting that the company's key drug candidate will fail to prove effective in critical phases of clinical trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Vera-Therapeutics-Inc.-VERA&v=1772702531071 "Short Shares Chart for the Company Vera Therapeutics Inc. (VERA)")
Shares shorted by market segment - Pharma immune
Vera Therapeutics (VERA) is a biotech company specializing in developing treatments for immunological diseases, particularly the rare kidney disease IgAN. This chart aggregates short positions across the biotech sector. It reflects the high level of risk and investor skepticism regarding clinical trials.
Shares shorted by the overall market
Vera Therapeutics (VERA) is a clinical-stage biotech (immunology). This indicator (`Short_All`) is a mirror of market fear. When it rises, investors panic and dump risk, especially unprofitable biotechs. This pessimism, visible on the chart, deprives VERA of access to the capital needed for expensive trials.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Vera Therapeutics Inc. (VERA)
Vera Therapeutics (VERA) is a biotech company focused on treating immunological diseases. Their lead candidate is for IgA nephropathy (a kidney disease). This chart measures hype. It shows "overbought" (above 70) on positive clinical trial news or "oversold" (below 30) amid trial delays or setbacks.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Vera-Therapeutics-Inc.-VERA&v=1772702531214 "RSI 14 indicator chart for the company's stock Vera Therapeutics Inc. (VERA)")
RSI 14 Market Segment - Pharma immune
Vera Therapeutics (VERA) is a biotech company developing drugs to treat serious immunological diseases. The RSI_14_Seg for "Pharma-immune" shows whether the entire biotech segment is overheated. The chart helps us understand: is VERA's volatility a reaction to its trials or just general hype in the sector?
RSI 14 for the overall market
Vera Therapeutics (VERA) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast VERA (Vera Therapeutics Inc.)
Vera Therapeutics is a biotech company focused on treating immunological diseases. Their main asset is Atacicept, a drug for the treatment of IgA nephropathy (a kidney disease). This chart shows the average analyst forecast. Their target price is a collective bet on the success of clinical trials and the drug's market potential.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-VERA-Vera-Therapeutics-Inc.&v=1772702531235 "A chart showing analyst consensus forecasts for the expected stock price. VERA (Vera Therapeutics Inc.)")
The difference between the consensus estimate and the actual stock price VERA (Vera Therapeutics Inc.)
Vera Therapeutics is a biotech company focused on developing drugs to treat severe immunological diseases, primarily IgA nephropathy (a kidney disease). This chart shows the difference between the market's current valuation of the company and the analyst consensus price target. This reflects their confidence in the success of clinical trials.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-VERA-Vera-Therapeutics-Inc.&v=1772702531244 "A chart showing the difference between the consensus forecast and the actual stock price. VERA (Vera Therapeutics Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
Vera Therapeutics is a late-stage biopharmaceutical company developing drugs to treat serious immunological kidney diseases (IgA nephropathy). This chart shows analysts' overall expectations for the pharmaceutical sector. It reflects whether experts believe new kidney treatments will be commercially successful.
Analysts' consensus forecast for the overall market share price
Vera Therapeutics (VERA) is a clinical-stage biopharmaceutical company focused on developing treatments for rare immunological kidney diseases. This is a high-risk scientific endeavor. This chart shows the overall risk appetite in the market, reflecting investors' willingness to fund lengthy and expensive clinical trials.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Vera Therapeutics Inc.
Vera Therapeutics is a clinical-stage biotech focused on immune diseases. Their lead candidate (atacicept) is a potential therapy for a rare kidney disease (IgA nephropathy). This chart represents pure R&D investment. It likely reflects investor confidence in successful clinical trials and the market potential of their lead drug, rather than revenue.
AKIMA Market Segment Index - Pharma immune
Vera Therapeutics (VERA) is a clinical-stage biotech focused on immunology; the company is developing a breakthrough drug (Atacicept) for the treatment of IgA nephropathy (a rare kidney disease). This summary metric evaluates R&D. The graph shows the average value for the segment. This is a benchmark: how does VERA's niche (IgAN) R&D focus differentiate it from the average pharma company?
The AKIM Index for the overall market
Vera Therapeutics is a clinical-stage biotech developing immunological therapies for the treatment of severe kidney disease (IgAN). This chart, which reflects the market average, is an indicator of risk appetite. It reveals the macro backdrop, which is critical for funding innovative companies like Vera.
